Business Context and Reporting Period
This Form 8-K filing by Miragen Therapeutics, Inc. (trading symbol: MGEN) reports on the results of its 2019 Annual Meeting of Stockholders held on June 19, 2019. The report was filed on June 21, 2019. The company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
The primary material event reported is the conclusion of the 2019 Annual Meeting. Key details include:
- Shareholder Participation: Of 30,926,219 shares outstanding, 26,408,340 shares (85.39%) were present or represented by proxy.
- Election of Directors: All seven nominees were re-elected. Notably, Jeffrey S. Hatfield received the highest number of "Withheld" votes (1,662,058) compared to other directors, though he was still re-elected.
- Auditor Ratification: Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly a disclosure of voting results.
Investor Verification Checklist
- Verify the specific reasons for the higher "Withheld" vote count for director Jeffrey S. Hatfield compared to other nominees.
- Confirm the company's current cash position and runway in separate filings (e.g., 10-Q or 10-K), as this 8-K contains no financial data.
- Review the full proxy statement for detailed biographies of the re-elected directors and any related party transactions.